Join the Oncology Voice Network. Join for Free
The Future MSL
medical science liaison MSL role evolution future of MSL analytics in MSL MSL diversity

The Future MSL


Share This Article


Summary

In this episode, Eddie Power joins to discuss the future landscape of the Medical Science Liaison (MSL) role. The conversation delves into emerging trends, including the integration of analytics to enhance MSL functions and the evolving responsibilities that may lead to new titles. Eddie explores how data delivery and strategy will shape MSL activities, alongside expanding stakeholder engagement. The episode also provides insights on preparing current MSLs for upcoming changes and offers advice to MSL leaders on fostering diversity, equity, and inclusion within their teams. The discussion wraps up with expressions of gratitude and appreciation for the listeners.

Learn more about…

👉 What factors will affect the MSL job and its trajectory into the future
👉 What credentials will be necessary for the future MSL and what might change
👉 What is on the horizon that makes the MSL role better (or worse) in the future
👉 Is the future of the MSL role in jeopardy at all due to AI and artificial intelligence
👉 Will new titles and responsibilities emerge for the MSL of the future
👉 Will the MSL of the future be more involved with the patient

Click for Source
medical science liaison, MSL role evolution, future of MSL, analytics in MSL, MSL diversity

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN